“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
The FDA's IND clearance is a pivotal moment for Accent Therapeutics, propelling our lead program into the clinical arena. ATX-559 has shown remarkable promise in preclinical studies, and we're excited to now evaluate its potential to meaningfully improve outcomes for patients facing these challenging malignancies....
Judo Bio has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines. The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates...
Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis. The deal, announced Monday, is the latest indicator that Lilly is still investing in new neuro drugs ahead of the FDA advisory committee for its Alzheimer’s drug donanemab...
"We are delighted to announce the backing of an exceptional investor syndicate who share our commitment to advancing innovative therapies for patients with cancer," said Shakti Narayan, PhD, JD, CEO of Accent Therapeutics. "These additional resources position us well to file INDs this year for...
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. Phase Ib trial for sovilnesib, Volastra’s second KIF18A inhibitor, is anticipated to open in Q1 2024....
HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors. The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-related adverse events. Disease control rate...
Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-HER3 ADC to be developed for patients with HER3-expressing tumors. Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicine. Investigational New Drug (IND) application planned in first half of 2024....